Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 pediatric PK and safety study of solriamfetol in narcolepsy
NL-OMON49961Phase 1Withdrawn
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of solriamfetol in narcolepsy (2 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Pharmacokinetics of single doses of solriamfetol. Planned start Jun 2020; status: withdrawn.
02
Drugs
solriamfetol
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NL-OMON49961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49961.